Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Stotz, Michael ^a   Szkandera, Joanna ^a   Seidel, Julia ^a   Stojakovic, Tatjana ^a   Samonigg, Hellmut ^a   Reitz, Daniel ^a   Gary, Thomas ^a   Kornprat, Peter ^a   Schaberl Moser, Renate ^a   Hoefler, Gerald ^a   Gerger, Armin ^a   Pichler, Martin ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; URIC ACID; TUMOR MARKER;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; FEMALE; GENDER; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; RETROSPECTIVE STUDY; URIC ACID BLOOD LEVEL; AGED; BLOOD; CARCINOMA, PANCREATIC DUCTAL; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL;

AGED; CARCINOMA, PANCREATIC DUCTAL; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; URIC ACID;

EID: 84929138413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104730     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians 63: 11-30.
2. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, et al. (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World journal of surgery 27: 324-329. (Pubitemid 36920145)
3. Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76: 1671-1677.
4. Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, et al. (2013) Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta oncologica 52: 1231-1233.
5. Heinemann V, Haas M, Boeck S (2013) Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 24: 2484-2492.
6. Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, et al. (2013) Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. Journal of clinical pathology 66: 753-757.
7. Fortner JG, Klimstra DS, Senie RT, Maclean BJ (1996) Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Annals of surgery 223: 147-153. (Pubitemid 26065207)
8. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, et al. (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Annals of surgery 246: 52-60. (Pubitemid 47012207)
9. Benckert C, Thelen A, Cramer T, Weichert W, Gaebelein G, et al. (2012) Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer. Surgery today 42: 169-176.
10. Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, et al. (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surgery today 29: 16-22. (Pubitemid 29058554)
11. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, et al. (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. British journal of cancer 109: 416-421.
12. Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, et al. (2013) A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 34: 2183-2188.
13. Szkandera J, Stotz M, Eisner F, Absenger G, Stojakovic T, et al. (2013) External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PloS one 8: e78225.
14. Hochberg J, Cairo MS (2008) Tumor lysis syndrome: current perspective. Haematologica 93: 9-13. (Pubitemid 351156145)
15. Lin H, Lin HX, Ge N, Wang HZ, Sun R, et al. (2013) Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiation oncology 8: 121.
16. Dziaman T, Banaszkiewicz Z, Roszkowski K, Gackowski D, Wisniewska E, et al. (2013) 8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. International journal of cancer Journal international du cancer.
17. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, et al. (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. British journal of cancer 109: 395-400.
18. Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, et al. (2014) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. British journal of cancer 110: 183-188.
19. Heinig M, Johnson RJ (2006) Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleveland Clinic journal of medicine 73: 1059-1064. (Pubitemid 44883981)
20. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521. (Pubitemid 37237047)
21. Shi Y, Zheng W, Rock KL (2000) Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America 97: 14590-14595. (Pubitemid 32016620)
22. Fabbrini E, Serafini M, Baric IC, Hazen SL, Klein S (2013) Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes.
23. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proceedings of the National Academy of Sciences of the United States of America 78: 6858-6862. (Pubitemid 12216861)
24. Jackson AL, Loeb LA (2001) The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutation research 477: 7-21. (Pubitemid 32480184)
25. Storz P (2005) Reactive oxygen species in tumor progression. Frontiers in bioscience: a journal and virtual library 10: 1881-1896.
26. Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. The Biochemical journal 313 (Pt 1): 17-29. (Pubitemid 26013419)
27. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, et al. (2005) Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. American journal of nephrology 25: 425-433. (Pubitemid 41433885)
28. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ (2007) Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. American journal of physiology Cell physiology 293: C584-596. (Pubitemid 47235197)
29. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, et al. (2011) Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60: 1258-1269.
30. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
31. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
32. Xu X, Rao GS, Groh V, Spies T, Gattuso P, et al. (2011) Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC cancer 11: 194.
33. Fini MA, Elias A, Johnson RJ, Wright RM (2012) Contribution of uric acid to cancer risk, recurrence, and mortality. Clinical and translational medicine 1: 16.
34. Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, et al. (2006) Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. Journal of pain and symptom management 31: 493-501.
35. Dhankhar R, Dahiya K, Sharma TK, Ghalaut VS, Atri R, et al. (2011) Diagnostic significance of adenosine deaminase, uric acid and C-reactive protein levels in patients of head and neck carcinoma. Clinical laboratory 57: 795-798.
36. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, et al. (2014) Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? The oncologist 19: 266-274.
37. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England journal of medicine 369: 1691-1703.